Tandem Diabetes Care, Inc.
NASDAQ:TNDMMedical - Devices
+$0.24 today
- Market cap
- $1.19B
- Beta
- 1.57
- P/E (TTM)
- -11.3
- EPS (TTM)
- -$1.38
Volume 2.35M
Average 2.43M
TNDM Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Tandem Diabetes Care, Inc.NASDAQ: TNDM
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin dips below year-ago levels
Q1 FY2026 selling, general & admin of $108.19M fell 5.0% year over year, behind the +5.8% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 4.3% from the prior quarter. Over 3 fiscal years it compounded at +9.0% a year.
Context
- Selling, general & admin amounted to 42.8% of revenue in FY2025, up 1.3 pp from a year earlier.
- Selling, general & admin increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 18 analysts of $453.39M (+4.4%) for the fiscal year ending Dec 2026, a slowdown from the +11.4% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $108.19M-4.3% QoQ
- Last fiscal yearDec 2025
- $434.13M+11.4% YoY
- LTMMar 2026
- $437.36M+5.8% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 434.13M USD
- Year-over-year change
- +11.4%
- 4-year CAGR
- +13.5%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 434.13M | +11.4% |
| FY2024 | 2024-12-31 | 389.82M | +10.6% |
| FY2023 | 2023-12-31 | 352.5M | +5.0% |
| FY2022 | 2022-12-31 | 335.68M | +28.4% |
| FY2021 | 2021-12-31 | 261.51M | — |
Selling, General & Admin vs competitors
How TNDM compares with its peers on the latest reported figures
- TNDM's LTM Mar 2026 selling, general & admin of $437.36M is the 4th highest of the 8 companies compared; the peer median is $173.21M.
- Its year-over-year change of +5.8% is the lowest of 6, against a peer median of +61.1%.
- Selling, general & admin amounts to 42.6% of revenue for TNDM, versus a peer median of 45.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $1.36B | +7.0% | +8.6% | 27.4% | |
| LTM Jun 2026 | $1.31B | +29.1% | +25.6% | 42.9% | |
MMEDMiniMed Group, Inc. Common Stock | LTM Jul 2026 | $1.24B | — | +7.2% | 38.4% |
| LTM Mar 2026 | $437.36M | +5.8% | +9.0% | 42.6% | |
| LTM Mar 2026 | $173.21M | +78.5% | +16.4% | 48.0% | |
| LTM Mar 2026 | $102.76M | +61.1% | +40.3% | 93.2% | |
| LTM Mar 2026 | $74.99M | +121.9% | +18.4% | 184.2% | |
| LTM Mar 2026 | $17.25M | — | +15.2% | — | |
MMEDVMiniMed Group, Inc. | — | — | — | — | — |
| Peer median (excluding TNDM) | $173.21M | +61.1% | +16.4% | 45.4% | |
Competitors are the stored peer set for TNDM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 702.8M | 801.22M | 747.72M | 940.2M | 1.01B |
| Cost of Revenue | 326.58M | 388.23M | 380.03M | 450.63M | 483.89M |
| Gross Profit | 376.22M | 412.99M | 367.69M | 489.57M | 530.85M |
| Gross Margin | 53.5% | 51.5% | 49.2% | 52.1% | 52.3% |
| Research & Development | 92.05M | 170.15M | 248.42M | 198.88M | 174.84M |
| Selling, General & Admin | 261.51M | 335.68M | 352.5M | 389.82M | 434.13M |
| Operating Expenses | 353.56M | 505.83M | 600.92M | 588.7M | 608.97M |
| Depreciation & Amortization | 13.85M | 14.33M | 15.72M | 158K | 17.67M |
| EBITDA | 34.06M | (74.21M) | (196.46M) | (99.13M) | (174.7M) |
| EBITDA Margin | 4.8% | -9.3% | -26.3% | -10.5% | -17.2% |
| Operating Income | 22.65M | (92.85M) | (233.23M) | (99.13M) | (78.12M) |
| Operating Margin | 3.2% | -11.6% | -31.2% | -10.5% | -7.7% |
| Interest Income | 674K | 6.06M | 22.86M | 17.99M | 9.09M |
| Interest Expense | 6.04M | 6.21M | 9.88M | 7.42M | 7.91M |
| Other Income / Expenses | (6.75M) | (4K) | 12.98M | 7.26M | (122.15M) |
| Income Before Tax | 15.9M | (92.85M) | (220.25M) | (91.87M) | (200.27M) |
| Pre-Tax Margin | 2.3% | -11.6% | -29.5% | -9.8% | -19.7% |
| Income Tax Expense | 335K | 1.74M | 2.36M | 4.16M | 4.44M |
| Net Income | 15.57M | (94.59M) | (222.61M) | (96.03M) | (204.71M) |
| Net Margin | 2.2% | -11.8% | -29.8% | -10.2% | -20.2% |
| EPS (Basic) | 0.25 | (1.47) | (3.43) | (1.47) | (3.04) |
| EPS (Diluted) | 0.24 | (1.47) | (3.43) | (1.47) | (3.04) |
| Weighted Avg Shares | 63M | 64.15M | 64.9M | 65.45M | 67.29M |
| Weighted Avg Shares (Diluted) | 64.35M | 64.15M | 64.97M | 65.45M | 67.29M |
Tandem Diabetes Care, Inc.
NASDAQ:TNDM
Intrinsic Alpha fair value
Locked
Current Price
$17.05
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.